3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
2
Dermatologic
2
Breast
2
Thoracic
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Melanoma
5
Lung Neoplasms
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
24
Nivolumab
19
atezolizumab
9
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
durvalumab
5
Ipilimumab
5
fludarabine
4
Trastuzumab
4
cemiplimab
3
cabozantinib
3
avelumab
3
Sunitinib
3
Biopsy
3
ulixertinib
2
toripalimab
2
tislelizumab
2
spartalizumab
2
sargramostim
2
relatlimab
2
palbociclib
2
lenvatinib
2
epacadostat
2
enzalutamide
2
cyclopropapyrroloindole
2
copanlisib
2
budigalimab
2
aldesleukin
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
poly ICLC
×
Thoracic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled